Nothing Special   »   [go: up one dir, main page]

Zuber et al., 2011 - Google Patents

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Zuber et al., 2011

View HTML
Document ID
7402960210093195451
Author
Zuber J
Shi J
Wang E
Rappaport A
Herrmann H
Sison E
Magoon D
Qi J
Blatt K
Wunderlich M
Taylor M
Johns C
Chicas A
Mulloy J
Kogan S
Brown P
Valent P
Bradner J
Lowe S
Vakoc C
Publication year
Publication venue
Nature

External Links

Snippet

Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modifications. Cancer cells are characterized by altered epigenetic landscapes, and commonly exploit the chromatin regulatory machinery to enforce oncogenic gene …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay

Similar Documents

Publication Publication Date Title
Zuber et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Xu et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
Zeid et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma
Morris IV et al. α-Ketoglutarate links p53 to cell fate during tumour suppression
Dawson et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
Shirai et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
Cañadas et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Knoechel et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Zheng et al. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination
Rathert et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Betancur et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
Yu et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
Lu et al. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development
Chi et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
Köhrer et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition
Ntziachristos et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
Fong et al. BET inhibitor resistance emerges from leukaemia stem cells
Rudat et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
Yoo et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma
Song et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network
Emmrich et al. miR-9 is a tumor suppressor in pediatric AML with t (8; 21)
Cao et al. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency
Fukazawa et al. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma
Oki et al. Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
Massett et al. A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival